Real-life data of Pasireotide LAR in acromegaly: a long-term follow-up.

ABSTRACT:

Objective

Pasireotide LAR (PAS-LAR) was released in Italy in 2017 to treat acromegaly patients resistant to SRLs (Somatostatin Receptors Ligands). The long-term follow-up data of PAS-LAR therapy in Italy are limited. This study aimed to evaluate the efficacy and safety of PAS-LAR in acromegaly.

Design

Patients with acromegaly in PAS-LAR treatment were enrolled in three tertiary Italian endocrinological centers and evaluated by a retrospective observational real-life multicentre study.

Methods

Patients have been studied before (baseline) and 1, 6, 12, 24 and > 36 months after PAS-LAR start. Clinical, biochemical, and pituitary magnetic resonance data were collected, along with information on adverse events. Acromegaly disease activity was classified according to the IG

SUBMITTER: Urbani C 

PROVIDER: S-EPMC11196287 | biostudies-literature | 2024 Jul

REPOSITORIES: biostudies-literature